Collegium Pharmaceutical, Inc. (COLL): Price and Financial Metrics


Collegium Pharmaceutical, Inc. (COLL): $23.02

0.14 (+0.61%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

COLL POWR Grades

  • Growth is the dimension where COLL ranks best; there it ranks ahead of 98.64% of US stocks.
  • The strongest trend for COLL is in Growth, which has been heading up over the past 179 days.
  • COLL's current lowest rank is in the Sentiment metric (where it is better than 6.36% of US stocks).

COLL Stock Summary

  • With a year-over-year growth in debt of 170.48%, COLLEGIUM PHARMACEUTICAL INC's debt growth rate surpasses 91.92% of about US stocks.
  • Over the past twelve months, COLL has reported earnings growth of -118.78%, putting it ahead of only 12.66% of US stocks in our set.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for COLL comes in at -58.84% -- higher than that of only 9.52% of stocks in our set.
  • If you're looking for stocks that are quantitatively similar to COLLEGIUM PHARMACEUTICAL INC, a group of peers worth examining would be NMIH, BRMK, ALCO, SAIC, and ITP.
  • COLL's SEC filings can be seen here. And to visit COLLEGIUM PHARMACEUTICAL INC's official web site, go to www.collegiumpharma.com.

COLL Valuation Summary

  • In comparison to the median Healthcare stock, COLL's EV/EBIT ratio is 1326.74% lower, now standing at -105.5.
  • COLL's price/earnings ratio has moved down 3.5 over the prior 92 months.

Below are key valuation metrics over time for COLL.

Stock Date P/S P/B P/E EV/EBIT
COLL 2022-11-25 2 3.7 -17.0 -105.5
COLL 2022-11-23 2 3.7 -16.8 -105.0
COLL 2022-11-22 2 3.7 -17.2 -106.2
COLL 2022-11-21 2 3.7 -16.9 -105.2
COLL 2022-11-18 2 3.7 -17.2 -106.1
COLL 2022-11-17 2 3.7 -16.8 -105.0

COLL Growth Metrics

    The year over year price growth rate now stands at -34%.
  • The 4 year price growth rate now stands at 25.57%.
  • Its 2 year net income to common stockholders growth rate is now at 440.33%.
COLL's revenue has moved up $359,964,000 over the prior 70 months.

The table below shows COLL's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 361.675 94.103 -42.837
2022-06-30 313.505 68.588 -35.248
2022-03-31 272.898 57.672 42.786
2021-12-31 276.868 103.557 71.517
2021-09-30 325.777 89.936 103.509
2021-06-30 326.11 106.862 106.749

COLL's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • COLL has a Quality Grade of B, ranking ahead of 83.9% of graded US stocks.
  • COLL's asset turnover comes in at 0.493 -- ranking 87th of 681 Pharmaceutical Products stocks.
  • IBIO, IRWD, and COCP are the stocks whose asset turnover ratios are most correlated with COLL.

The table below shows COLL's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.493 0.608 0.369
2021-03-31 0.498 0.612 0.422
2020-12-31 0.483 0.580 0.341
2020-09-30 0.552 0.522 0.367
2020-06-30 0.638 0.460 0.266
2020-03-31 0.772 0.391 2.336

COLL Price Target

For more insight on analysts targets of COLL, see our COLL price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $26.71 Average Broker Recommendation 1.56 (Moderate Buy)

COLL Stock Price Chart Interactive Chart >

Price chart for COLL

COLL Price/Volume Stats

Current price $23.02 52-week high $23.27
Prev. close $22.88 52-week low $14.04
Day low $22.36 Volume 284,300
Day high $23.27 Avg. volume 304,585
50-day MA $18.70 Dividend yield N/A
200-day MA $17.95 Market Cap 772.83M

Collegium Pharmaceutical, Inc. (COLL) Company Bio


Collegium Pharmaceuticals is a specialty pharmaceutical company focused on developing a portfolio of products that incorporate its patent-protected DETERx technology platform for the treatment of chronic pain and other diseases. The company was founded in 2002 and is based in Canton, Massachusetts.


COLL Latest News Stream


Event/Time News Detail
Loading, please wait...

COLL Latest Social Stream


Loading social stream, please wait...

View Full COLL Social Stream

Latest COLL News From Around the Web

Below are the latest news stories about COLLEGIUM PHARMACEUTICAL INC that investors may wish to consider to help them evaluate COLL as an investment opportunity.

Collegium to Participate in Piper Sandler 34th Annual Healthcare Conference

STOUGHTON, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company, today announced that management will participate in a fireside chat at the Piper Sandler 34th Annual Healthcare Conference being held in New York, NY from November 29 to December 1, 2022. Details of the event are as follows:Fireside Chat Date and Time: Wednesday, November 30, 2022, at 1:30 p.m. ET The fireside chat will be webcast live and ca

Yahoo | November 22, 2022

Collegium Pharmaceutical Third Quarter 2022 Earnings: EPS Beats Expectations

Collegium Pharmaceutical ( NASDAQ:COLL ) Third Quarter 2022 Results Key Financial Results Revenue: US$127.0m (up 61...

Yahoo | November 8, 2022

Collegium Pharmaceutical, Inc. 2022 Q2 - Results - Earnings Call Presentation

The following slide deck was published by Collegium Pharmaceutical, Inc. in conjunction with their 2022 Q2 earnings call.

...

SA Transcripts on Seeking Alpha | November 4, 2022

Collegium Pharmaceutical (COLL) Receives a Buy from Needham

In a report released today, Serge Belanger from Needham maintained a Buy rating on Collegium Pharmaceutical (COLL - Research Report), with a price target of $34.00. The company's shares closed yesterday at $18.03.According to TipRanks, Belanger is an analyst with an average return of -5.0% and a 37.76% success rate. Belanger covers the Healthcare sector, focusing on stocks such as Pacira Pharmaceuticals, Revance Therapeutics, and KalVista Pharmaceuticals.Collegium Pharmaceutical has an analyst consensus of Moderate Buy, with a price target consensus of $34.00.See the top stocks recommended by analysts >>The company has a one-year high of $22.89 and a one-year low of $14.04.

Ryan Adist on TipRanks | November 4, 2022

Collegium Pharmaceutical (COLL) Lags Q3 Earnings Estimates

Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of -9.84% and 2.72%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | November 3, 2022

Read More 'COLL' Stories Here

COLL Price Returns

1-mo 27.68%
3-mo 28.82%
6-mo 46.44%
1-year 30.72%
3-year 11.48%
5-year 35.89%
YTD 23.23%
2021 -6.74%
2020 -2.67%
2019 19.86%
2018 -6.99%
2017 18.56%

Continue Researching COLL

Here are a few links from around the web to help you further your research on Collegium Pharmaceutical Inc's stock as an investment opportunity:

Collegium Pharmaceutical Inc (COLL) Stock Price | Nasdaq
Collegium Pharmaceutical Inc (COLL) Stock Quote, History and News - Yahoo Finance
Collegium Pharmaceutical Inc (COLL) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8518 seconds.